Emergency Medicine Residents’ Association
AdvocacySupport
Mifepristone access restrictions
Citizen Petition from Nicholas W. Brown, Attorney General of Washington, et. al.
FDA-2025-P-3287-0001Other
Comments
19
Last activity Jul 27, 2026
Deadline
--
Net supportiSupport minus oppose · campaigns included
+65%
+65% excluding campaigns
Document
Details
The document's own metadata, straight from the source system.
- Title
- Citizen Petition from Nicholas W. Brown, Attorney General of Washington, et. al.
- Posted
- Aug 26, 2025
- Comment period
- Aug 26, 2025 – ?
- Topics
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Include campaigns
Analyzed 17 of 19 comments
89%· analysis in progress
Stance breakdown
+65%
Net support
Support14Oppose3Not yet analyzed2
Aggregates include form-letter campaigns. Excluding them, net support is +65% across organic comments.
Who commented
Breakdown by commenter type.
Advocacy
11
Academic
4
Business
2
Not yet analyzed
2
Comments over time
Weekly arrivals, stacked by stance.
Posted Aug 26, 2025
Sep 15Oct 20Nov 3Nov 24Feb 16Jun 29Jul 27
Support14Oppose3Other0
Support × commenter type
How each type splits across stance.
Support
Oppose
Other
Advocacy
73%
27%
0%
Academic
100%
0%
0%
Business
100%
0%
0%
Issues raised
The docket's canonical issues. Select one to browse its comments.
Position map
Who stands where on each issue?
Every non-silent position is backed by an excerpt from the comment.
Issues shown
Choose up to five.
| Organization | Mifepristone access restrictions | Mifepristone safety and efficacy |
|---|---|---|
Emergency Medicine Residents’ Association AdvocacySupport The Emergency Medicine Residents’ Association (EMRA) expresses full support for several citizen petitions requesting tha | · |
5 organization-typed comments could not be identified.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
Filter:
- Nov 6, 2025Comment from Guttmacher InstituteSupportAdvocacy📎 Attachment
The Guttmacher Institute, a research and policy organization, submits this comment in support of citizen petitions regarding the FDA's regulation of mifepristone. They argue that the drug is safe and effective, citing extensive scientific consensus and global usage, while criticizing anti-abortion narratives that mischaracterize routine medical care as serious adverse events.
Read comment → - Oct 21, 2025Comment from Charlotte Lozier InstituteOpposeAdvocacy📎 Attachment
The Charlotte Lozier Institute, a research and education institute of Susan B. Anthony Pro-Life America, opposes the citizen petition to remove the mifepristone REMS program. They argue that the FDA should restore previous safeguards, such as in-person prescribing, citing concerns over data reliability, potential safety risks, and the lack of adequate medical oversight in telehealth models.
Read comment →